Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941031 · ClinicalTrials.gov registry record · Phase 2
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
A Phase 2 study of Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 404
- Enrollment target
- 20
- Study locations
NCT00941031: Completed Phase 2 study of Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals.
NCT00941031 is a Phase 2 study of Chronic Plaque-type Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 404 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (204% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00941031, a Phase 2 study of Chronic Plaque-type Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 404 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
Primary Outcome
Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AIN457
- DRUG AIN457A
Study Locations (20)
California
- Novartis Investigative Site - Pasadena
- Novartis Investigative Site - San Diego
Georgia
- Novartis Investigative Site - Newnan
- Novartis Investigative Site - Snellville
Illinois
- Novartis Investigative Site - Champaign
- Novartis Investigative Site - Springfield
Michigan
- Novartis Investigative Site - Clinton Twp.
- Novartis Investigative Site - Detroit
Nebraska
- Novartis Investigative Site - Omaha
- Novartis Investigative Site - Omaha
Alabama
- Novartis Investigative Site - Birmingham
Arkansas
- Novartis Investigative Site - Little Rock
Indiana
- Novartis Investigative Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00941031 record still lists
NCT00941031 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (204% higher).
The record links to 1 condition, with Chronic Plaque-type Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00941031 names 20 study sites across 15 states, led by California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00941031 about?
NCT00941031 is a clinical study titled "AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis". The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body area is affected by the disease (compared to placebo).
What is the current status of trial NCT00941031?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 404 participants. The study started on 2009-07. Estimated completion is 2010-12.
What conditions does trial NCT00941031 study?
This clinical trial studies the following conditions: Chronic Plaque-type Psoriasis.
What interventions are being tested in trial NCT00941031?
The interventions under investigation include: Placebo (DRUG), AIN457 (DRUG), AIN457A (DRUG).
Who is sponsoring clinical trial NCT00941031?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00941031 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00941031's enrollment target sits among peer trials
404 95th of 2000 higher than 1,905 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia